RapidAI

RapidAI grew out of stroke imaging research and has become one of the most widely deployed clinical AI platforms in healthcare. Its core promise is speed: when a large vessel occlusion or aneurysm is present, minutes matter, and RapidAI automatically detects, quantifies and communicates those findings to the treating team so decisions can be made sooner. Beyond neuro, the platform spans cardiac and vascular, trauma and emergency, oncology and radiology support workflows, all delivered through a single enterprise layer.

The Rapid Enterprise platform is built for scale rather than single-department pilots. It combines deep clinical AI with workflow integration, secure enterprise infrastructure, analytics dashboards and the ability to plug in partner AI models. That means a health system can standardize on one vendor-agnostic platform, connect imaging to action across service lines, and give administrators the visibility they need to track utilization and impact.

Adoption is aimed squarely at organizations, not individuals. Hospitals and radiology groups typically start with a demo request, then go through implementation and clinician education via RapidU before running the tools in production. The company reports FDA-cleared solutions, use in more than 2,500 hospitals globally and a publication library of over 750 peer-reviewed studies supporting its algorithms.